The effectiveness of Colonzak in patients with various clinical variants of irritable bowel syndrome

Main Article Content

D.T. Janelidze

Abstract

Background. The etiological causes of irritable bowel syndrome (IBS) symptoms have not been fully established. The lack of a clear understanding of the pathogenetic mechanisms of the development of one or another functional intestinal disease, including IBS, taking into account the presence of various structural and morphological disorders in the intestinal wall, dictates the need to search for new drugs, the action of which will be directed to different links in the pathogenesis of intestinal diseases. The aim of the study is to examine the efficacy and safety of Colonzak using in patients with various clinical variants of irritable bowel syndrome. Materials and methods. We examined 42 patients with a verified diagnosis of IBS (14 — IBS type 1; 14 — IBS type 2; 9 — IBS type 3; 5 — IBS type 4) aged 25 to 45 years (average age 35 ± 1.7 years). In all IBS patients, organic intestinal pathology was excluded during colonoscopy. IBS was diagnosed according to Rome IV criteria. In addition to lifestyle modification and adherence to dietary rules, depending on the type of IBS, all patients (regardless of the IBS variant) received monotherapy with Colonzak in a dosage of 1 capsule 2 times a day in the morning and in the evening before meals for 30 days. All patients completed the IBS Symptoms Severity Score (IBS-SSS) questionnaire before and after the study. The results were statistically processed using Excel 2017 (Microsoft) and Statistica 13. Results. The study showed that Colonzak containing probiotic strains of bifidobacteria, prebiotic inulin, and butyric acid can be considered as a safe, well-tolerated, and highly effective drug for the treatment of patients with different types of IBS. In patients with IBS, the use of Colonzak was accompanied by a statistically significant increase in the clinical effectiveness of treatment. Conclusions. Our study has confirmed the clinical efficacy of Colonzak as a multicomponent protector for a colon in IBS. The results obtained allow us to recommend the widespread use of Сolonzak in the complex treatment of patients with different types of IBS.

Article Details

How to Cite
Janelidze, D. (2020). The effectiveness of Colonzak in patients with various clinical variants of irritable bowel syndrome. GASTROENTEROLOGY, 54(4), 234–238. https://doi.org/10.22141/2308-2097.54.4.2020.216843
Section
Original Researches

References

Aziz I, Törnblom H, Palsson OS, Whitehead WE, Simrén M. How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors. Am J Gastroenterol. 2018 Jul;113(7):1017-1025. doi:10.1038/s41395-018-0074-z.

Gwee KA, Ghoshal UC, Chen M. Irritable bowel syndrome in Asia: Pathogenesis, natural history, epidemiology, and management. J Gastroenterol Hepatol. 2018 Jan;33(1):99-110. doi:10.1111/jgh.13987.

Vork L, Weerts ZZRM, Mujagic Z, et al. Rome III vs Rome IV criteria for irritable bowel syndrome: A comparison of clinical characteristics in a large cohort study. Neurogastroenterol Motil. 2018 Feb;30(2). doi:10.1111/nmo.13189.

Song KH, Jung HK, Kim HJ, et al. Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. J Neurogastroenterol Motil. 2018 Apr 30;24(2):197-215. doi:10.5056/jnm17145.

Cañón M, Ruiz AJ, Rondón M, Alvarado J. Prevalence of irritable bowel syndrome and health-related quality of life in adults aged 18 to 30 years in a Colombian University: an electronic survey. Ann Gastroenterol. 2017;30(1):67-75. doi:10.20524/aog.2016.0093.

Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016 Feb 19:S0016-5085(16)00223-7. doi:10.1053/j.gastro.2016.02.032.

Houghton LA, Heitkemper M, Crowell M, et al. Age, Gender and Women's Health and the Patient. Gastroenterology. 2016 Feb 15:S0016-5085(16)00183-9. doi:10.1053/j.gastro.2016.02.017.

Wu JC, Chan AO, Chan YW, Cheung GC, Cheung TK, Kwan AC, Leung VK, Mak AD, Sze WC, Wong R. The current treatment landscape of irritable bowel syndrome in adults in Hong Kong: consensus statements. Hong Kong Med J. 2017 Dec;23(6):641-647. doi:10.12809/hkmj177060.

US Department of Health and Human Services (HHS); US Department of Agriculture (USDA). 2015-2020 Dietary Guidelines for Americans. 8th ed. Washington; 2015. 144 p.

Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology. 2017 Apr;152(5):1042-1054.e1. doi:10.1053/j.gastro.2016.12.039.

Wong RK, Yang C, Song GH, Wong J, Ho KY. Melatonin regulation as a possible mechanism for probiotic (VSL#3) in irritable bowel syndrome: a randomized double-blinded placebo study. Dig Dis Sci. 2015 Jan;60(1):186-194. doi:10.1007/s10620-014-3299-8.

Yoon H, Park YS, Lee DH, Seo JG, Shin CM, Kim N. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr. 2015 Sep;57(2):129-134. doi:10.3164/jcbn.15-14.

Chen B, Kim JJ, Zhang Y, Du L, Dai N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol. 2018 Jul;53(7):807-818. doi:10.1007/s00535-018-1476-9.